April 07, 2026
A class of investors has reached a deal with Biogen Inc. to avoid a trial and resolve a suit over statements executives made as they launched an Alzheimer's drug, according to a Tuesday filing in Massachusetts federal court.
October 07, 2025
Biogen Inc. said a class of investors suing over alleged misleading statements in connection with the rollout of the company's Alzheimer's drug should not be allowed to needlessly delay resolution by filing an amended complaint expanding the class period and adding new legal theories and claims.
February 04, 2025
A Massachusetts federal judge on Tuesday said he was reminded of a grade school lesson in long division as he explained his reasoning behind granting class certification and cutting short the class period in a suit against drugmaker Biogen Inc. on the orders of the First Circuit.
May 13, 2024
A proposed class of Biogen shareholders urged a Massachusetts federal court to certify their now-revived class action alleging the drugmaker made misleading statements about a deficient Alzheimer's drug, arguing it can sufficiently lead the suit with Block & Leviton LLP as class counsel.
March 29, 2023
A Massachusetts federal judge tossed a suit Wednesday brought by shareholders accusing Biogen of making misleading statements about a deficient Alzheimer's drug, ruling the complaint is a "house of cards" full of mischaracterizations.
July 28, 2022
Healthcare giant Biogen denied making any misleading statements to its investors Wednesday in a motion to dismiss a securities class action alleging the company knew an Alzheimer's drug was deficient but went ahead with its production anyway.
February 08, 2022
Biogen was hit with a proposed class action Monday from investors whose shares plummeted after a controversial new Alzheimer's drug failed to deliver the financial gains they expected.